Giulia Ippolito Lane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giulia Ippolito Lane has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
- Anne Pelletier Cameron
Department of Urology, University of Michigan, Ann Arbor, USA
12 shared publications - J. Quentin Clemens
Department of Urology, University of Michigan Medical School, Ann Arbor, MI, United States
9 shared publications - John T. Stoffel
Department of Urology University of Michigan Ann Arbor Michigan USA
8 shared publications Priyanka Gupta
Department of Urology, University of Michigan, Ann Arbor, Michigan
8 shared publicationsJ. Quentin Clemens
University of Michigan Ann Arbor Michigan USA
6 shared publications- Ariana L. Smith
Division of Urology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
5 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Wiley in Neurourology and Urodynamics
Factors Impacting Continuation of Onabotulinum Toxin Therapy for Idiopathic and Neurogenic Urgency Urinary Incontinence
Introduction: We investigated demographic, diagnostic, and socioeconomic variables associated with continuation and discontinuation of onabotulinum toxin (BTX) therapy in adult patients treated for idiopathic and neurogenic urgency urinary incontinence (UUI). Methods: Patients who initiated BTX for UUI between 2015 and 2018 at a tertiary academic referral center were identified from CPT codes and followed through 2020 ( n = 723). The cohort was divided into patients who continued BTX therapy (received ≥1 BTX treatment within 2 years of initial injection) (Group A), and patients who stopped BTX (received no additional BTX for at least 2 years after the last injection) (Group B). Demographic variables were extracted using chart review and administrative data. Socioeconomic differences were estimated using affluence index (AI) and disadvantage index (DI) from their last botox injection, calculated using U.S. census tract indicators. AI factors include household income, professions of household members, and educational background. DI factors include neighborhood proportion of female‐headed households, receiving public assistance or not, household income level, and level of employment. Indexes ranged from 0.0 (least affluent or disadvantaged) to 1.0 (most affluent or advantaged). Results: The mean cohort age ( n = 723) was 57% and 69% were female. After the initial injection, 40% received additional injections within 2 years (Group A) and 60% did not (Group B). There were no demographic differences between groups. Univariate comparison of affluence and disadvantage indexes revealed Group A affluence was not significantly different (AI = 0.38 vs 0.37, p = 0.2) but was slightly less disadvantaged (DI = 0.072, vs. 0.081; p = 0.036) than Group B. Multivariable analysis including demographic and socioeconomic factors demonstrated that higher affluence index was associated with lower odds of BTX discontinuation (OR = 0.90 per 0.1‐unit increase, 95% CI: 0.82–0.99, p = 0.029), while there was insufficient evidence of an association between disadvantage index and discontinuation (OR = 1.23 per 0.1‐unit increase, 95% CI: 0.99–1.54, p = 0.06). After adding neurogenic versus non‐neurogenic etiology of UUI, the socioeconomic associations were no longer significant. Patients with a non‐neurogenic diagnosis had significantly greater odds of BTX discontinuation than patients with a neurogenic diagnosis (OR = 1.97, 95% CI: 1.35–2.89, p < 0.001). Conclusion: Approximately 40% of patients continued BTX treatment for UUI beyond the initial injection period. Neurogenic diagnosis was strongly associated with treatment persistence, with non‐neurogenic patients demonstrating greater odds of discontinuation. Socioeconomic factors were not independently associated with discontinuation after adjustment for clinical diagnosis. Clinical Trial Registration: This is a retrospective study with IRB approval. This study is not a clinical trial and will not be registered as a clinical trial.
- 29 October 2026
- Published by Wiley in Neurourology and Urodynamics
Open AccessFactors Impacting Continuation of Onabotulinum Toxin Therapy for Idiopathic and Neurogenic Urgency Urinary Incontinence
Introduction: We investigated demographic, diagnostic, and socioeconomic variables associated with continuation and discontinuation of onabotulinum toxin (BTX) therapy in adult patients treated for idiopathic and neurogenic urgency urinary incontinence (UUI). Methods: Patients who initiated BTX for UUI between 2015 and 2018 at a tertiary academic referral center were identified from CPT codes and followed through 2020 ( n = 723). The cohort was divided into patients who continued BTX therapy (received ≥1 BTX treatment within 2 years of initial injection) (Group A), and patients who stopped BTX (received no additional BTX for at least 2 years after the last injection) (Group B). Demographic variables were extracted using chart review and administrative data. Socioeconomic differences were estimated using affluence index (AI) and disadvantage index (DI) from their last botox injection, calculated using U.S. census tract indicators. AI factors include household income, professions of household members, and educational background. DI factors include neighborhood proportion of female‐headed households, receiving public assistance or not, household income level, and level of employment. Indexes ranged from 0.0 (least affluent or disadvantaged) to 1.0 (most affluent or advantaged). Results: The mean cohort age ( n = 723) was 57% and 69% were female. After the initial injection, 40% received additional injections within 2 years (Group A) and 60% did not (Group B). There were no demographic differences between groups. Univariate comparison of affluence and disadvantage indexes revealed Group A affluence was not significantly different (AI = 0.38 vs 0.37, p = 0.2) but was slightly less disadvantaged (DI = 0.072, vs. 0.081; p = 0.036) than Group B. Multivariable analysis including demographic and socioeconomic factors demonstrated that higher affluence index was associated with lower odds of BTX discontinuation (OR = 0.90 per 0.1‐unit increase, 95% CI: 0.82–0.99, p = 0.029), while there was insufficient evidence of an association between disadvantage index and discontinuation (OR = 1.23 per 0.1‐unit increase, 95% CI: 0.99–1.54, p = 0.06). After adding neurogenic versus non‐neurogenic etiology of UUI, the socioeconomic associations were no longer significant. Patients with a non‐neurogenic diagnosis had significantly greater odds of BTX discontinuation than patients with a neurogenic diagnosis (OR = 1.97, 95% CI: 1.35–2.89, p < 0.001). Conclusion: Approximately 40% of patients continued BTX treatment for UUI beyond the initial injection period. Neurogenic diagnosis was strongly associated with treatment persistence, with non‐neurogenic patients demonstrating greater odds of discontinuation. Socioeconomic factors were not independently associated with discontinuation after adjustment for clinical diagnosis. Clinical Trial Registration: This is a retrospective study with IRB approval. This study is not a clinical trial and will not be registered as a clinical trial.
- Open Access
- 5 October 2026
- Published by Wiley in Neurourology and Urodynamics
Lived Experiences of Emotional Distress Among Patients With Lower Urinary Tract Symptoms: A Mixed‐Methods Study
Purpose: We aimed to describe the association of lower urinary tract symptoms (LUTS) with emotional distress using questionnaires and qualitative interviews. Methods: We used a convergent parallel mixed methods design to examine relationships between the LURN Symptom Index‐29 (LURN SI‐29) questionnaire and emotional distress, measured by the Patient‐Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depression Short Forms and the Perceived Stress Scale. Quantitative analyses assessed correlations between the SI‐29 total and subscale scores and emotional distress measures. Qualitative interviews explored the emotional impact of LUTS, with representative quotations used to contextualize quantitative findings. Results: The total and pain subscale scores of the LURN SI‐29 demonstrated the strongest positive correlations with anxiety ( r = 0.25–0.33), depression ( r = 0.24–0.30), and stress ( r = 0.21–0.28). Urgency, incontinence and voiding subscales had weaker associations, while nocturia showed minimal or slighting negative correlations (| r | < 0.12). Although most of the relationships were statistically significant, effect sizes were generally small. Qualitative narratives converged with these findings, describing how pain, unpredictability, and loss of control contributed to anxiety, depression, and stress. Conclusions: Pain and overall LUTS burden were the primary contributors to emotional distress, whereas nocturia played a minimal role. Despite cohort selection for urinary urgency, pain was a driver of emotional distress, highlighting the need to assess bladder‐related pain and its psychosocial impacts in LUTS care. Trial Registration: NCT02485808.
- 5 October 2026
- Published by Wiley in Neurourology and Urodynamics
Open AccessLived Experiences of Emotional Distress Among Patients With Lower Urinary Tract Symptoms: A Mixed‐Methods Study
Purpose: We aimed to describe the association of lower urinary tract symptoms (LUTS) with emotional distress using questionnaires and qualitative interviews. Methods: We used a convergent parallel mixed methods design to examine relationships between the LURN Symptom Index‐29 (LURN SI‐29) questionnaire and emotional distress, measured by the Patient‐Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depression Short Forms and the Perceived Stress Scale. Quantitative analyses assessed correlations between the SI‐29 total and subscale scores and emotional distress measures. Qualitative interviews explored the emotional impact of LUTS, with representative quotations used to contextualize quantitative findings. Results: The total and pain subscale scores of the LURN SI‐29 demonstrated the strongest positive correlations with anxiety ( r = 0.25–0.33), depression ( r = 0.24–0.30), and stress ( r = 0.21–0.28). Urgency, incontinence and voiding subscales had weaker associations, while nocturia showed minimal or slighting negative correlations (| r | < 0.12). Although most of the relationships were statistically significant, effect sizes were generally small. Qualitative narratives converged with these findings, describing how pain, unpredictability, and loss of control contributed to anxiety, depression, and stress. Conclusions: Pain and overall LUTS burden were the primary contributors to emotional distress, whereas nocturia played a minimal role. Despite cohort selection for urinary urgency, pain was a driver of emotional distress, highlighting the need to assess bladder‐related pain and its psychosocial impacts in LUTS care. Trial Registration: NCT02485808.
- Open Access
Erectile dysfunction and its associations with type 2 diabetes, neuropathy, metabolic syndrome in men seeking specialty care for urinary urgency: a cross-sectional study
Objectives: To examine the relationships between erectile dysfunction (ED) and diabetes and related complications, metabolic syndrome (MetS) components and lower urinary tract symptoms (LUTSs) in a cohort of men seeking care for urinary urgency and other LUTSs. Design: Cross-sectional analysis of baseline data from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN II) Urinary Urgency Phenotyping study, which aimed to characterise subgroups of persons with urinary urgency. Setting: Six clinical sites of the NIH/NIDDK-sponsored Symptoms of LURN, US. Participants: 305 men enrolled in the LURN II Urinary Urgency Phenotyping study who provided complete baseline erectile function data. Primary and secondary outcome measures: Erectile function was assessed using the erectile function domain of the International Index of Erectile Function (IIEF). MetS components, diabetes-related complications and LUTS severity were compared between men with and without ED. Results: Among 305 men with urinary urgency, 181 (59%) had ED. Men with ED were significantly older and more likely to have type 2 diabetes (25% vs 12%, p<0.01). Peripheral neuropathy (38% vs 25%, p=0.02) and autonomic neuropathy (57% vs 43%, p=0.02) were more common in men with ED. The majority of men without ED correspondingly did not report MetS components. Finally, men with ED reported more severe LUTS, including higher total LUTS scores and a greater burden of storage symptoms. Conclusions: These data suggest that diabetes as well as markers of metabolic dysfunction are important factors in ED in treatment-seeking men with urinary urgency and other LUTS. Studies evaluating the mechanisms contributing to these interactions are warranted for targeting effective prevention or treatment.
Open AccessErectile dysfunction and its associations with type 2 diabetes, neuropathy, metabolic syndrome in men seeking specialty care for urinary urgency: a cross-sectional study
Objectives: To examine the relationships between erectile dysfunction (ED) and diabetes and related complications, metabolic syndrome (MetS) components and lower urinary tract symptoms (LUTSs) in a cohort of men seeking care for urinary urgency and other LUTSs. Design: Cross-sectional analysis of baseline data from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN II) Urinary Urgency Phenotyping study, which aimed to characterise subgroups of persons with urinary urgency. Setting: Six clinical sites of the NIH/NIDDK-sponsored Symptoms of LURN, US. Participants: 305 men enrolled in the LURN II Urinary Urgency Phenotyping study who provided complete baseline erectile function data. Primary and secondary outcome measures: Erectile function was assessed using the erectile function domain of the International Index of Erectile Function (IIEF). MetS components, diabetes-related complications and LUTS severity were compared between men with and without ED. Results: Among 305 men with urinary urgency, 181 (59%) had ED. Men with ED were significantly older and more likely to have type 2 diabetes (25% vs 12%, p<0.01). Peripheral neuropathy (38% vs 25%, p=0.02) and autonomic neuropathy (57% vs 43%, p=0.02) were more common in men with ED. The majority of men without ED correspondingly did not report MetS components. Finally, men with ED reported more severe LUTS, including higher total LUTS scores and a greater burden of storage symptoms. Conclusions: These data suggest that diabetes as well as markers of metabolic dysfunction are important factors in ED in treatment-seeking men with urinary urgency and other LUTS. Studies evaluating the mechanisms contributing to these interactions are warranted for targeting effective prevention or treatment.
- 10 August 2026
- Published by Wiley in Neurourology and Urodynamics
Retrospective Evaluation of Contemporary Complication Rates and Severity After Suprapubic Tube Placement by Urology and Interventional Radiology
Introduction: To compare complication rates and severity associated with suprapubic tube (SPT) placement by urology versus interventional radiology (IR) and to identify patient factors associated with increased complication risk. Methods: A retrospective, single‐center review from 2017 to 2022 examined patients who underwent SPT placement by urology or IR. Patients without 90‐day follow‐up were excluded. Patient demographics, indications for SPT placement, and perioperative, 30‐ and 90‐day postoperative complications were recorded using the Clavien‐Dindo (CD) classification system. Outcomes were compared between urology and IR. Multivariable logistic regression assessed associations between preoperative factors, specialty and major complications. Results: A total of 266 patients were included (179 urology, 87 IR). Median age was 68 years; 64% were male, and 56% had neurogenic bladder. Median catheter size was 18 Fr and 20 Fr for urology and IR, respectively ( p = 0.05). Perioperative complication rates were low and comparable (5.6% urology vs. 5.8% IR, p = 0.80). Most 30‐ and 90‐day complications were minor (CD grades 1–2), primarily urinary tract infections and SPT malfunction, while major complications (CD grades 3–5) were uncommon. Overall, 90‐day complication rates were similar (48% urology vs. 45% IR, p = 0.66), though major complications occurred more frequently in the IR group (11% vs. 5.2%, p = 0.04). On multivariable analysis, specialty, history of pelvic radiation, and prior pelvic surgery were not significantly associated with severe complications. Conclusion: Urology and IR have comparable, low complication rates for SPT placement. Perioperative complications are infrequent and more severe. Longer‐term complications were common but more likely to be minor, primarily urinary tract infections or SPT dislodgement with higher rates of urinary tract infections in SPTs placed by IR.
- 10 August 2026
- Published by Wiley in Neurourology and Urodynamics
Retrospective Evaluation of Contemporary Complication Rates and Severity After Suprapubic Tube Placement by Urology and Interventional Radiology
Introduction: To compare complication rates and severity associated with suprapubic tube (SPT) placement by urology versus interventional radiology (IR) and to identify patient factors associated with increased complication risk. Methods: A retrospective, single‐center review from 2017 to 2022 examined patients who underwent SPT placement by urology or IR. Patients without 90‐day follow‐up were excluded. Patient demographics, indications for SPT placement, and perioperative, 30‐ and 90‐day postoperative complications were recorded using the Clavien‐Dindo (CD) classification system. Outcomes were compared between urology and IR. Multivariable logistic regression assessed associations between preoperative factors, specialty and major complications. Results: A total of 266 patients were included (179 urology, 87 IR). Median age was 68 years; 64% were male, and 56% had neurogenic bladder. Median catheter size was 18 Fr and 20 Fr for urology and IR, respectively ( p = 0.05). Perioperative complication rates were low and comparable (5.6% urology vs. 5.8% IR, p = 0.80). Most 30‐ and 90‐day complications were minor (CD grades 1–2), primarily urinary tract infections and SPT malfunction, while major complications (CD grades 3–5) were uncommon. Overall, 90‐day complication rates were similar (48% urology vs. 45% IR, p = 0.66), though major complications occurred more frequently in the IR group (11% vs. 5.2%, p = 0.04). On multivariable analysis, specialty, history of pelvic radiation, and prior pelvic surgery were not significantly associated with severe complications. Conclusion: Urology and IR have comparable, low complication rates for SPT placement. Perioperative complications are infrequent and more severe. Longer‐term complications were common but more likely to be minor, primarily urinary tract infections or SPT dislodgement with higher rates of urinary tract infections in SPTs placed by IR.
- 1 August 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (2) , 174-176
Treat-to-Target Approach: A New Paradigm for the Treatment of Idiopathic Overactive Bladder
- 1 August 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (2) , 174-176
Treat-to-Target Approach: A New Paradigm for the Treatment of Idiopathic Overactive Bladder
- Open Access
Additional therapies after minimally invasive treatments in women with OAB
Objective: To evaluate the rate, timing, and predictors of additional therapy among women with idiopathic overactive bladder (OAB) following initial minimally invasive therapies (MIT). Study Design: Retrospective single center cohort study of women with idiopathic OAB treated between 2012 and 2021. Using ICD and procedural codes, we identified women who underwent posterior tibial nerve stimulation (PTNS), sacral neuromodulation (SNM), or intradetrusor onabotulinumtoxinA (BTX). The primary outcome was receipt of additional OAB treatments including OAB medication and/or a different MIT after initial clinical response to MIT. Kaplan-Meier analysis estimated time to additional therapies; Cox proportional hazards and random survival forest models identified predictors. Results: 1,007 women were included (PTNS: 459; SNM: 192; BTX: 356). At three years, 68% of PTNS patients, 52% of BTX patients, and 40% of SNM women required additional therapies with most patients receiving a prescription for additional pharmacotherapy rather than receiving a different MIT. Median time to additional treatments was 12 months (PTNS), 30 months (BTX), and 53 months (SNM). Multiple indications for SNM were associated with decreased hazard for AT (HR 0.56 95% CI 0.33-0.95, p=0.03) while recurrent urinary tract infections were associated with needing additional therapies in the BTX cohort (HR 1.8, 95% CI: 1.1-3.2). Conclusions: Following initial MIT for idiopathic OAB, many women required additional treatment within three years, with most receiving a prescription for pharmacotherapy rather than receiving another MIT. Why This Matters: Overactive bladder (OAB) affects over 33% of women in the United States, and current AUA/SUFU guidelines have shifted from traditional stepwise therapy toward shared decision-making and multimodal treatment. While minimally invasive therapies (MIT) are effective options for OAB, real-world data on patient trajectories after MIT initiation, including rates of treatment augmentation, crossover, or return to pharmacotherapy, remain limited. This retrospective cohort of 1,007 women with idiopathic OAB provides novel data on post-MIT OAB therapy, with 40–68% of patients requiring additional therapy within three years. We noted significant differences in baseline characteristics and treatment tractories between the groups of patients stratified by first MIT and could not directly compare rates of AT between MITs. Factors associated with additional therapy included recurrent urinary tract infections after BTX, whereas multiple indications for SNM were associated with decreased use of AT. Most women who required additional treatment received pharmacotherapy rather than crossing over to a different MIT. These findings reinforce that OAB management is a dynamic, ongoing process rather than a one-time intervention, and that additional therapy is common. Clinicians can use these data to set realistic expectations during counseling, framing additional therapy as a common and anticipated part of the treatment trajectory rather than a treatment failure.
Open AccessAdditional therapies after minimally invasive treatments in women with OAB
Objective: To evaluate the rate, timing, and predictors of additional therapy among women with idiopathic overactive bladder (OAB) following initial minimally invasive therapies (MIT). Study Design: Retrospective single center cohort study of women with idiopathic OAB treated between 2012 and 2021. Using ICD and procedural codes, we identified women who underwent posterior tibial nerve stimulation (PTNS), sacral neuromodulation (SNM), or intradetrusor onabotulinumtoxinA (BTX). The primary outcome was receipt of additional OAB treatments including OAB medication and/or a different MIT after initial clinical response to MIT. Kaplan-Meier analysis estimated time to additional therapies; Cox proportional hazards and random survival forest models identified predictors. Results: 1,007 women were included (PTNS: 459; SNM: 192; BTX: 356). At three years, 68% of PTNS patients, 52% of BTX patients, and 40% of SNM women required additional therapies with most patients receiving a prescription for additional pharmacotherapy rather than receiving a different MIT. Median time to additional treatments was 12 months (PTNS), 30 months (BTX), and 53 months (SNM). Multiple indications for SNM were associated with decreased hazard for AT (HR 0.56 95% CI 0.33-0.95, p=0.03) while recurrent urinary tract infections were associated with needing additional therapies in the BTX cohort (HR 1.8, 95% CI: 1.1-3.2). Conclusions: Following initial MIT for idiopathic OAB, many women required additional treatment within three years, with most receiving a prescription for pharmacotherapy rather than receiving another MIT. Why This Matters: Overactive bladder (OAB) affects over 33% of women in the United States, and current AUA/SUFU guidelines have shifted from traditional stepwise therapy toward shared decision-making and multimodal treatment. While minimally invasive therapies (MIT) are effective options for OAB, real-world data on patient trajectories after MIT initiation, including rates of treatment augmentation, crossover, or return to pharmacotherapy, remain limited. This retrospective cohort of 1,007 women with idiopathic OAB provides novel data on post-MIT OAB therapy, with 40–68% of patients requiring additional therapy within three years. We noted significant differences in baseline characteristics and treatment tractories between the groups of patients stratified by first MIT and could not directly compare rates of AT between MITs. Factors associated with additional therapy included recurrent urinary tract infections after BTX, whereas multiple indications for SNM were associated with decreased use of AT. Most women who required additional treatment received pharmacotherapy rather than crossing over to a different MIT. These findings reinforce that OAB management is a dynamic, ongoing process rather than a one-time intervention, and that additional therapy is common. Clinicians can use these data to set realistic expectations during counseling, framing additional therapy as a common and anticipated part of the treatment trajectory rather than a treatment failure.
- Open Access
- 28 July 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (9) , e70366
3D MR Fingerprinting for Quantitative Bladder Wall T 1 , T 2 , and M 0 Mapping in Healthy Subjects at 1.5 T and 3 T
Current diagnostic tests for lower urinary tract symptoms (LUTS) do not assess tissue‐level alterations in the bladder wall. This study assesses the feasibility of 3D magnetic resonance fingerprinting (MRF) for simultaneous T 1 , T 2 , and proton density (M 0 ) mapping of the bladder wall in healthy subjects at 1.5 T and 3 T. A 3D MRF acquisition was combined with a deep image prior reconstruction to achieve whole‐bladder T 1 , T 2 , and M 0 mapping in 11.8 min at an acquired voxel size of 1 × 1 × 3 mm 3 (interpolated to 0.5 × 0.5 × 1.5 mm 3 ). Twenty‐nine healthy subjects (14 female, 18–78 years) were enrolled, with 16 scanned at both 1.5 T and 3 T. Conventional maps were acquired using MOLLI and T 2 ‐prepared GRE sequences. Maps were analyzed by measuring mean global and regional T 1 and T 2 values, with spatial heterogeneity assessed using the coefficient of variation (CV). Bladder wall thickness (BWT) was measured from synthetic weighted images derived from MRF maps, compared to reference values from conventional T 2 ‐weighted MRI. Mean global MRF bladder wall measurements were 984 53 ms (T 1 ), 51.4 5.6 ms (T 2 ), and 4.5 1.6 mm (BWT) at 1.5 T and 1468 118 ms (T 1 ), 43.5 4.0 ms (T 2 ), and 4.3 1.6 mm (BWT) at 3 T. MRF T 1 values were significantly lower than MOLLI at 1.5 T (bias −151 ms) but not significantly different at 3 T. MRF T 2 values were significantly lower (by 7–8 ms) than T 2 ‐prepared GRE at both field strengths. MRF exhibited lower CV than MOLLI T 1 mapping at 1.5 T. BWT from synthetic images exhibited excellent agreement (bias .1 mm) with conventional T 2 ‐weighted images. Regionally, T 1 and T 2 tended to be higher in the dome and posterior wall. In an exploratory analysis, a positive association between age and T 2 was observed. In conclusion, 3D MRF of the bladder wall is feasible in healthy subjects, providing a baseline for translational studies to characterize pathological remodeling in LUTS.
- 28 July 2026
- Published by Wiley in NMR in Biomedicine
- Vol. 39 (9) , e70366
Open Access3D MR Fingerprinting for Quantitative Bladder Wall T 1 , T 2 , and M 0 Mapping in Healthy Subjects at 1.5 T and 3 T
Current diagnostic tests for lower urinary tract symptoms (LUTS) do not assess tissue‐level alterations in the bladder wall. This study assesses the feasibility of 3D magnetic resonance fingerprinting (MRF) for simultaneous T 1 , T 2 , and proton density (M 0 ) mapping of the bladder wall in healthy subjects at 1.5 T and 3 T. A 3D MRF acquisition was combined with a deep image prior reconstruction to achieve whole‐bladder T 1 , T 2 , and M 0 mapping in 11.8 min at an acquired voxel size of 1 × 1 × 3 mm 3 (interpolated to 0.5 × 0.5 × 1.5 mm 3 ). Twenty‐nine healthy subjects (14 female, 18–78 years) were enrolled, with 16 scanned at both 1.5 T and 3 T. Conventional maps were acquired using MOLLI and T 2 ‐prepared GRE sequences. Maps were analyzed by measuring mean global and regional T 1 and T 2 values, with spatial heterogeneity assessed using the coefficient of variation (CV). Bladder wall thickness (BWT) was measured from synthetic weighted images derived from MRF maps, compared to reference values from conventional T 2 ‐weighted MRI. Mean global MRF bladder wall measurements were 984 53 ms (T 1 ), 51.4 5.6 ms (T 2 ), and 4.5 1.6 mm (BWT) at 1.5 T and 1468 118 ms (T 1 ), 43.5 4.0 ms (T 2 ), and 4.3 1.6 mm (BWT) at 3 T. MRF T 1 values were significantly lower than MOLLI at 1.5 T (bias −151 ms) but not significantly different at 3 T. MRF T 2 values were significantly lower (by 7–8 ms) than T 2 ‐prepared GRE at both field strengths. MRF exhibited lower CV than MOLLI T 1 mapping at 1.5 T. BWT from synthetic images exhibited excellent agreement (bias .1 mm) with conventional T 2 ‐weighted images. Regionally, T 1 and T 2 tended to be higher in the dome and posterior wall. In an exploratory analysis, a positive association between age and T 2 was observed. In conclusion, 3D MRF of the bladder wall is feasible in healthy subjects, providing a baseline for translational studies to characterize pathological remodeling in LUTS.
- 1 May 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (5) , 637-638
Reply: Vaginal Lasers for Treating Stress Urinary Incontinence in Women: An Abridged Cochrane Systematic Review and Meta-Analysis
- 1 May 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (5) , 637-638
Reply: Vaginal Lasers for Treating Stress Urinary Incontinence in Women: An Abridged Cochrane Systematic Review and Meta-Analysis
- Open Access
- 7 February 2026
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 21 (1) , 1
Shared Decision Making, Decision Aids and Patient Reported Outcome Measures for Overactive Bladder Care: A Review
Purpose of Review: Shared decision making (SDM) is integral to clinical decision making for OAB. SDM is a collaborative process that takes patients’ values, preferences, and goals into account when deciding on their treatment options. Decision aids (DAs) can support SDM and patient-reported outcomes (PROs) help to assess the outcomes most important to the patient. Recent Findings: Twenty-five articles were retrieved and reviewed. Our search for literature about SDM in OAB found that physician recommendation is a key decisional component for patients yet that physicians’ priorities may differ widely from patients’ preferences. We evaluated currently available decision aids for OAB and found that none of the peer reviewed aids are publicly available, though non-peer reviewed, paper-based decision aids are available online. At least 10 PROs are available for OAB, these are regularly used in trials of efficacy and are increasingly being implemented in clinical practice. Finally, artificial intelligence applications such as large language models and machine learning based clinical risk prediction tools are emerging as a new facet to augment SDM, but there are limitations on the quality and the clinical implementation of these tools. Summary: Decision aids and patient reported outcome measures are integral to the delivery of patient-centered, individualized, shared decision making for OAB. Despite this, few freely available DAs exist and many PROs are available, which makes comparison of outcomes between treatments challenging. Emerging AI technologies may further augment the SDM however require validation prior to clinical use.
- 7 February 2026
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 21 (1) , 1
Open AccessShared Decision Making, Decision Aids and Patient Reported Outcome Measures for Overactive Bladder Care: A Review
Purpose of Review: Shared decision making (SDM) is integral to clinical decision making for OAB. SDM is a collaborative process that takes patients’ values, preferences, and goals into account when deciding on their treatment options. Decision aids (DAs) can support SDM and patient-reported outcomes (PROs) help to assess the outcomes most important to the patient. Recent Findings: Twenty-five articles were retrieved and reviewed. Our search for literature about SDM in OAB found that physician recommendation is a key decisional component for patients yet that physicians’ priorities may differ widely from patients’ preferences. We evaluated currently available decision aids for OAB and found that none of the peer reviewed aids are publicly available, though non-peer reviewed, paper-based decision aids are available online. At least 10 PROs are available for OAB, these are regularly used in trials of efficacy and are increasingly being implemented in clinical practice. Finally, artificial intelligence applications such as large language models and machine learning based clinical risk prediction tools are emerging as a new facet to augment SDM, but there are limitations on the quality and the clinical implementation of these tools. Summary: Decision aids and patient reported outcome measures are integral to the delivery of patient-centered, individualized, shared decision making for OAB. Despite this, few freely available DAs exist and many PROs are available, which makes comparison of outcomes between treatments challenging. Emerging AI technologies may further augment the SDM however require validation prior to clinical use.
- 12 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500677
Experiences of Transgender and Gender-Nonconforming Patients With Genitourinary and Gynecologic Cancers: A Qualitative Study
PURPOSE: We hypothesized that transgender and gender-nonconforming (TGNC) patients diagnosed with genitourinary (GU) and gynecologic (GYN) cancers may experience unique challenges and barriers to care because of association of these organs with sex assigned at birth but not gender identity. We aimed to explore their experiences in this qualitative study. MATERIALS AND METHODS: TGNC adults diagnosed with a GU/GYN cancer completed an anonymous survey probing experiences with cancer diagnosis, treatment, and clinicians, with the option to complete an additional interview. Participants were accrued to thematic saturation. Analysis included descriptive statistics, open coding, and development of themes. RESULTS: Twenty-one patients completed a survey, and 16 completed an interview. Qualitative analysis yielded six key themes: (1) clinician dismissal and assumptions about gender identity and preferences, (2) inadequate clinician knowledge about TGNC health, (3) avoidance of oncologic care due to dysphoria and fear of discrimination, (4) increased dysphoria associated with GU/GYN cancer, (5) importance of gender identity in patients' decision making, and desire to discuss gender-affirming goals, and (6) wide spectrum of reactions to GU/GYN cancer diagnosis, associated with charged feelings toward affected organ. CONCLUSION: For TGNC patients with GU/GYN cancers, gender identity matters, both for clinical decision making and patients' emotional experience. Clinicians can partner with patients through this challenging journey to ensure that patients feel safe and supported and can make treatment decisions that align with their gender-affirming goals.
- 12 January 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2500677
Experiences of Transgender and Gender-Nonconforming Patients With Genitourinary and Gynecologic Cancers: A Qualitative Study
PURPOSE: We hypothesized that transgender and gender-nonconforming (TGNC) patients diagnosed with genitourinary (GU) and gynecologic (GYN) cancers may experience unique challenges and barriers to care because of association of these organs with sex assigned at birth but not gender identity. We aimed to explore their experiences in this qualitative study. MATERIALS AND METHODS: TGNC adults diagnosed with a GU/GYN cancer completed an anonymous survey probing experiences with cancer diagnosis, treatment, and clinicians, with the option to complete an additional interview. Participants were accrued to thematic saturation. Analysis included descriptive statistics, open coding, and development of themes. RESULTS: Twenty-one patients completed a survey, and 16 completed an interview. Qualitative analysis yielded six key themes: (1) clinician dismissal and assumptions about gender identity and preferences, (2) inadequate clinician knowledge about TGNC health, (3) avoidance of oncologic care due to dysphoria and fear of discrimination, (4) increased dysphoria associated with GU/GYN cancer, (5) importance of gender identity in patients' decision making, and desire to discuss gender-affirming goals, and (6) wide spectrum of reactions to GU/GYN cancer diagnosis, associated with charged feelings toward affected organ. CONCLUSION: For TGNC patients with GU/GYN cancers, gender identity matters, both for clinical decision making and patients' emotional experience. Clinicians can partner with patients through this challenging journey to ensure that patients feel safe and supported and can make treatment decisions that align with their gender-affirming goals.